Summary

The global Endometrial Cancer Therapeutics market size is predicted to grow from US$ million in 2025 to US$ million in 2031; it is expected to grow at a CAGR of %from 2025 to 2031.
The global pharmaceutical market is 1475 billion USD in 2022, growing at a CAGR of 5% during the next six years. The pharmaceutical market includes chemical drugs and biological drugs. For biologics is expected to 381 billion USD in 2022. In comparison, the chemical drug market is estimated to increase from 1005 billion in 2018 to 1094 billion U.S. dollars in 2022. The pharmaceutical market factors such as increasing demand for healthcare, technological advancements, and the rising prevalence of chronic diseases, increase in funding from private & government organizations for development of pharmaceutical manufacturing segments and rise in R&D activities for drugs. However, the industry also faces challenges such as stringent regulations, high costs of research and development, and patent expirations. Companies need to continuously innovate and adapt to these challenges to stay competitive in the market and ensure their products reach patients in need. Additionally, the COVID-19 pandemic has highlighted the importance of vaccine development and supply chain management, further emphasizing the need for pharmaceutical companies to be agile and responsive to emerging public health needs.
LPI (LP Information)' newest research report, the “Endometrial Cancer Therapeutics Industry Forecast” looks at past sales and reviews total world Endometrial Cancer Therapeutics sales in 2024, providing a comprehensive analysis by region and market sector of projected Endometrial Cancer Therapeutics sales for 2025 through 2031. With Endometrial Cancer Therapeutics sales broken down by region, market sector and sub-sector, this report provides a detailed analysis in US$ millions of the world Endometrial Cancer Therapeutics industry.
This Insight Report provides a comprehensive analysis of the global Endometrial Cancer Therapeutics landscape and highlights key trends related to product segmentation, company formation, revenue, and market share, latest development, and M&A activity. This report also analyses the strategies of leading global companies with a focus on Endometrial Cancer Therapeutics portfolios and capabilities, market entry strategies, market positions, and geographic footprints, to better understand these firms’ unique position in an accelerating global Endometrial Cancer Therapeutics market.
This Insight Report evaluates the key market trends, drivers, and affecting factors shaping the global outlook for Endometrial Cancer Therapeutics and breaks down the forecast by Type, by Application, geography, and market size to highlight emerging pockets of opportunity. With a transparent methodology based on hundreds of bottom-up qualitative and quantitative market inputs, this study forecast offers a highly nuanced view of the current state and future trajectory in the global Endometrial Cancer Therapeutics.
This report presents a comprehensive overview, market shares, and growth opportunities of Endometrial Cancer Therapeutics market by product type, application, key players and key regions and countries.
Segmentation by Type:
Chemotherapy
Hormone Therapy
Radiation Therapy
Surgery
Segmentation by Application:
Research Institutes
Hospitals & Clinics
This report also splits the market by region:
Americas
United States
Canada
Mexico
Brazil
APAC
China
Japan
Korea
Southeast Asia
India
Australia
Europe
Germany
France
UK
Italy
Russia
Middle East & Africa
Egypt
South Africa
Israel
Turkey
GCC Countries
The below companies that are profiled have been selected based on inputs gathered from primary experts and analyzing the company's coverage, product portfolio, its market penetration.
Bayer AG
F. Hoffman La Roche Ltd.
Bristol-Myers Squibb Company
Merck KGaA
Novartis AG
Takeda Pharmaceutical Company Limited
Eli Lilly and Company
Sanofi
GlaxoSmithKline plc
ArQule, Inc.

ページTOPに戻る

Table of Contents

1 Scope of the Report
1.1 Market Introduction
1.2 Years Considered
1.3 Research Objectives
1.4 Market Research Methodology
1.5 Research Process and Data Source
1.6 Economic Indicators
1.7 Currency Considered
1.8 Market Estimation Caveats
2 Executive Summary
2.1 World Market Overview
2.1.1 Global Endometrial Cancer Therapeutics Market Size (2020-2031)
2.1.2 Endometrial Cancer Therapeutics Market Size CAGR by Region (2020 VS 2024 VS 2031)
2.1.3 World Current & Future Analysis for Endometrial Cancer Therapeutics by Country/Region (2020, 2024 & 2031)
2.2 Endometrial Cancer Therapeutics Segment by Type
2.2.1 Chemotherapy
2.2.2 Hormone Therapy
2.2.3 Radiation Therapy
2.2.4 Surgery
2.3 Endometrial Cancer Therapeutics Market Size by Type
2.3.1 Endometrial Cancer Therapeutics Market Size CAGR by Type (2020 VS 2024 VS 2031)
2.3.2 Global Endometrial Cancer Therapeutics Market Size Market Share by Type (2020-2025)
2.4 Endometrial Cancer Therapeutics Segment by Application
2.4.1 Research Institutes
2.4.2 Hospitals & Clinics
2.5 Endometrial Cancer Therapeutics Market Size by Application
2.5.1 Endometrial Cancer Therapeutics Market Size CAGR by Application (2020 VS 2024 VS 2031)
2.5.2 Global Endometrial Cancer Therapeutics Market Size Market Share by Application (2020-2025)
3 Endometrial Cancer Therapeutics Market Size by Player
3.1 Endometrial Cancer Therapeutics Market Size Market Share by Player
3.1.1 Global Endometrial Cancer Therapeutics Revenue by Player (2020-2025)
3.1.2 Global Endometrial Cancer Therapeutics Revenue Market Share by Player (2020-2025)
3.2 Global Endometrial Cancer Therapeutics Key Players Head office and Products Offered
3.3 Market Concentration Rate Analysis
3.3.1 Competition Landscape Analysis
3.3.2 Concentration Ratio (CR3, CR5 and CR10) & (2023-2025)
3.4 New Products and Potential Entrants
3.5 Mergers & Acquisitions, Expansion
4 Endometrial Cancer Therapeutics by Region
4.1 Endometrial Cancer Therapeutics Market Size by Region (2020-2025)
4.2 Global Endometrial Cancer Therapeutics Annual Revenue by Country/Region (2020-2025)
4.3 Americas Endometrial Cancer Therapeutics Market Size Growth (2020-2025)
4.4 APAC Endometrial Cancer Therapeutics Market Size Growth (2020-2025)
4.5 Europe Endometrial Cancer Therapeutics Market Size Growth (2020-2025)
4.6 Middle East & Africa Endometrial Cancer Therapeutics Market Size Growth (2020-2025)
5 Americas
5.1 Americas Endometrial Cancer Therapeutics Market Size by Country (2020-2025)
5.2 Americas Endometrial Cancer Therapeutics Market Size by Type (2020-2025)
5.3 Americas Endometrial Cancer Therapeutics Market Size by Application (2020-2025)
5.4 United States
5.5 Canada
5.6 Mexico
5.7 Brazil
6 APAC
6.1 APAC Endometrial Cancer Therapeutics Market Size by Region (2020-2025)
6.2 APAC Endometrial Cancer Therapeutics Market Size by Type (2020-2025)
6.3 APAC Endometrial Cancer Therapeutics Market Size by Application (2020-2025)
6.4 China
6.5 Japan
6.6 South Korea
6.7 Southeast Asia
6.8 India
6.9 Australia
7 Europe
7.1 Europe Endometrial Cancer Therapeutics Market Size by Country (2020-2025)
7.2 Europe Endometrial Cancer Therapeutics Market Size by Type (2020-2025)
7.3 Europe Endometrial Cancer Therapeutics Market Size by Application (2020-2025)
7.4 Germany
7.5 France
7.6 UK
7.7 Italy
7.8 Russia
8 Middle East & Africa
8.1 Middle East & Africa Endometrial Cancer Therapeutics by Region (2020-2025)
8.2 Middle East & Africa Endometrial Cancer Therapeutics Market Size by Type (2020-2025)
8.3 Middle East & Africa Endometrial Cancer Therapeutics Market Size by Application (2020-2025)
8.4 Egypt
8.5 South Africa
8.6 Israel
8.7 Turkey
8.8 GCC Countries
9 Market Drivers, Challenges and Trends
9.1 Market Drivers & Growth Opportunities
9.2 Market Challenges & Risks
9.3 Industry Trends
10 Global Endometrial Cancer Therapeutics Market Forecast
10.1 Global Endometrial Cancer Therapeutics Forecast by Region (2026-2031)
10.1.1 Global Endometrial Cancer Therapeutics Forecast by Region (2026-2031)
10.1.2 Americas Endometrial Cancer Therapeutics Forecast
10.1.3 APAC Endometrial Cancer Therapeutics Forecast
10.1.4 Europe Endometrial Cancer Therapeutics Forecast
10.1.5 Middle East & Africa Endometrial Cancer Therapeutics Forecast
10.2 Americas Endometrial Cancer Therapeutics Forecast by Country (2026-2031)
10.2.1 United States Market Endometrial Cancer Therapeutics Forecast
10.2.2 Canada Market Endometrial Cancer Therapeutics Forecast
10.2.3 Mexico Market Endometrial Cancer Therapeutics Forecast
10.2.4 Brazil Market Endometrial Cancer Therapeutics Forecast
10.3 APAC Endometrial Cancer Therapeutics Forecast by Region (2026-2031)
10.3.1 China Endometrial Cancer Therapeutics Market Forecast
10.3.2 Japan Market Endometrial Cancer Therapeutics Forecast
10.3.3 Korea Market Endometrial Cancer Therapeutics Forecast
10.3.4 Southeast Asia Market Endometrial Cancer Therapeutics Forecast
10.3.5 India Market Endometrial Cancer Therapeutics Forecast
10.3.6 Australia Market Endometrial Cancer Therapeutics Forecast
10.4 Europe Endometrial Cancer Therapeutics Forecast by Country (2026-2031)
10.4.1 Germany Market Endometrial Cancer Therapeutics Forecast
10.4.2 France Market Endometrial Cancer Therapeutics Forecast
10.4.3 UK Market Endometrial Cancer Therapeutics Forecast
10.4.4 Italy Market Endometrial Cancer Therapeutics Forecast
10.4.5 Russia Market Endometrial Cancer Therapeutics Forecast
10.5 Middle East & Africa Endometrial Cancer Therapeutics Forecast by Region (2026-2031)
10.5.1 Egypt Market Endometrial Cancer Therapeutics Forecast
10.5.2 South Africa Market Endometrial Cancer Therapeutics Forecast
10.5.3 Israel Market Endometrial Cancer Therapeutics Forecast
10.5.4 Turkey Market Endometrial Cancer Therapeutics Forecast
10.6 Global Endometrial Cancer Therapeutics Forecast by Type (2026-2031)
10.7 Global Endometrial Cancer Therapeutics Forecast by Application (2026-2031)
10.7.1 GCC Countries Market Endometrial Cancer Therapeutics Forecast
11 Key Players Analysis
11.1 Bayer AG
11.1.1 Bayer AG Company Information
11.1.2 Bayer AG Endometrial Cancer Therapeutics Product Offered
11.1.3 Bayer AG Endometrial Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.1.4 Bayer AG Main Business Overview
11.1.5 Bayer AG Latest Developments
11.2 F. Hoffman La Roche Ltd.
11.2.1 F. Hoffman La Roche Ltd. Company Information
11.2.2 F. Hoffman La Roche Ltd. Endometrial Cancer Therapeutics Product Offered
11.2.3 F. Hoffman La Roche Ltd. Endometrial Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.2.4 F. Hoffman La Roche Ltd. Main Business Overview
11.2.5 F. Hoffman La Roche Ltd. Latest Developments
11.3 Bristol-Myers Squibb Company
11.3.1 Bristol-Myers Squibb Company Company Information
11.3.2 Bristol-Myers Squibb Company Endometrial Cancer Therapeutics Product Offered
11.3.3 Bristol-Myers Squibb Company Endometrial Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.3.4 Bristol-Myers Squibb Company Main Business Overview
11.3.5 Bristol-Myers Squibb Company Latest Developments
11.4 Merck KGaA
11.4.1 Merck KGaA Company Information
11.4.2 Merck KGaA Endometrial Cancer Therapeutics Product Offered
11.4.3 Merck KGaA Endometrial Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.4.4 Merck KGaA Main Business Overview
11.4.5 Merck KGaA Latest Developments
11.5 Novartis AG
11.5.1 Novartis AG Company Information
11.5.2 Novartis AG Endometrial Cancer Therapeutics Product Offered
11.5.3 Novartis AG Endometrial Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.5.4 Novartis AG Main Business Overview
11.5.5 Novartis AG Latest Developments
11.6 Takeda Pharmaceutical Company Limited
11.6.1 Takeda Pharmaceutical Company Limited Company Information
11.6.2 Takeda Pharmaceutical Company Limited Endometrial Cancer Therapeutics Product Offered
11.6.3 Takeda Pharmaceutical Company Limited Endometrial Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.6.4 Takeda Pharmaceutical Company Limited Main Business Overview
11.6.5 Takeda Pharmaceutical Company Limited Latest Developments
11.7 Eli Lilly and Company
11.7.1 Eli Lilly and Company Company Information
11.7.2 Eli Lilly and Company Endometrial Cancer Therapeutics Product Offered
11.7.3 Eli Lilly and Company Endometrial Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.7.4 Eli Lilly and Company Main Business Overview
11.7.5 Eli Lilly and Company Latest Developments
11.8 Sanofi
11.8.1 Sanofi Company Information
11.8.2 Sanofi Endometrial Cancer Therapeutics Product Offered
11.8.3 Sanofi Endometrial Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.8.4 Sanofi Main Business Overview
11.8.5 Sanofi Latest Developments
11.9 GlaxoSmithKline plc
11.9.1 GlaxoSmithKline plc Company Information
11.9.2 GlaxoSmithKline plc Endometrial Cancer Therapeutics Product Offered
11.9.3 GlaxoSmithKline plc Endometrial Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.9.4 GlaxoSmithKline plc Main Business Overview
11.9.5 GlaxoSmithKline plc Latest Developments
11.10 ArQule, Inc.
11.10.1 ArQule, Inc. Company Information
11.10.2 ArQule, Inc. Endometrial Cancer Therapeutics Product Offered
11.10.3 ArQule, Inc. Endometrial Cancer Therapeutics Revenue, Gross Margin and Market Share (2020-2025)
11.10.4 ArQule, Inc. Main Business Overview
11.10.5 ArQule, Inc. Latest Developments
12 Research Findings and Conclusion